Discoveries in Multiple Myeloma
CtDNA possible biomarker to predict relapse in multiple myeloma
Using circulating tumor DNA to predict relapse after autologous stem cell transplantation in patients with multiple myeloma showed feasibility in a study presented at the virtual ASCO Annual Meeting.
Wearable sleep monitors may give insight into HRQoL in multiple myeloma
Mobile wearables that monitor sleep may give insight into health-related quality of life in patients with newly diagnosed multiple myeloma, according to a presentation from the virtual ASCO Annual Meeting.
BCMA-directed CAR-T still shows deep, durable response in heavily pretreated myeloma
Long-term results from the KarMMa trial continued to yield frequent deep and durable responses with idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in heavily pretreated patients with relapsed or refractory multiple myeloma.
Elranatamab shows efficacy in relapsed, refractory multiple myeloma
Subcutaneous elranatamab demonstrated efficacy and a manageable safety profile in patients with relapsed or refractory multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.
Non-invasive, inexpensive analytical tool predicts survival in multiple myeloma
Post-induction of a mass spectrometry tool called Mass-Fix predicted survival outcomes among patients with multiple myeloma participating on the STAMINA trial.
Isatuximab regimen demonstrates PFS benefit in relapsed, refractory multiple myeloma
Isatuximab plus pomalidomide and low-dose dexamethasone continued to show significant improvement in time to next treatment and PFS2 compared with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma, according to updated results from the ICARIA-MM study.
Neurologic adverse events manageable after CAR-T in multiple myeloma
Neurologic adverse events were generally manageable in patients with multiple myeloma after receiving ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy, according to CARTITUDE-2 data presented at the virtual ASCO Annual Meeting.
Daratumumab may improve PFS for patients with myeloma and high-risk cytogenetics
Adding daratumumab to backbone regimens improved PFS for patients with multiple myeloma and high-risk cytogenetics, both in the first-line and relapsed or refractory setting, according to data presented at ASCO20 Virtual Scientific Program.
Selinexor could be new ‘backbone’ in myeloma treatment
Selinexor and daratumumab in combination with dexamethasone was effective in patients with relapsed/refractory multiple myeloma, according to a presentation from ASCO20 Virtual Scientific Program.
Rapid steroid tapering appears safe in myeloma treated with daratumumab
Rapid corticosteroid tapering over 2 weeks was safe in patients with relapsed or refractory multiple myeloma who received subcutaneous daratumumab, according to findings presented at ASCO20 Virtual Scientific Program.